RxDoctor Payments DataLook up a doctor →

Jack Chapman, MD

Ophthalmology · Gainesville, GANPI 1689662751

Payments from drug & device makers

$305,191in general payments, 2019–2025

Across 543 payments — averaging $562.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$145K
  • Alcon Research LLC$62K
  • Lensar, Inc.$54K
  • Alcon$26K
  • Bausch & Lomb Americas Inc.$5K
  • Nordic Pharma, Inc.$3K
  • plus $10K from 27 others

What the payments were for

  • Consulting fees$71,90630%
  • Speaking & faculty fees$123,57251%
  • Travel & lodging$27,66011%
  • Food & beverage$20,2238%
  • Education$1590%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$305,191 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$318,534
Medicare patients
801
Services billed
2,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost55$25,827
RestasisCyclosporine22$21,272
Latanoprost523$6,870
Travoprost33$6,081
AzoptBrinzolamide11$4,131
RocklatanNetarsudil Mesylat/Latanoprost11$3,632
Brimonidine Tartrate104$3,363
ZioptanTafluprost/Pf11$2,774
Timolol Maleate105$2,032
Dorzolamide Hcl105$1,549
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat62$953
Prednisolone Acetate27$737
Ketorolac Tromethamine14$369
Levobunolol Hcl13$231
ErythromycinErythromycin Base12$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$577$47,09977 claims
AlconAzopt$25,570$4,13111 claims
Aerie Pharmaceuticals, Inc.Rocklatan$74$3,63211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →